ParkinsonFranceV1, PubMed, Curation, bibRecord, 001647

Apomorphine increases blood glucose concentrations in Parkinson's disease.

Identifieur interne : 001647 ( PubMed/Curation ); précédent : 001646; suivant : 001648

Apomorphine increases blood glucose concentrations in Parkinson's disease.

Auteurs : F. Tison [France] ; N. Fouillet ; P. Henry

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 1994.

RBID : pubmed:8149364

English descriptors

KwdEn :
- Aged, Apomorphine (adverse effects), Apomorphine (therapeutic use), Blood Glucose (metabolism), Humans, Levodopa (therapeutic use), Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson Disease, Secondary (drug therapy).
MESH :
- chemical , adverse effects : Apomorphine.
- chemical , metabolism : Blood Glucose.
- chemical , therapeutic use : Apomorphine, Levodopa.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease, Parkinson Disease, Secondary.
- Aged, Humans.

Abstract

Data from studies indicate that blood glucose levels may be influenced by stimulation of central D1 and D2 dopamine receptors. This is modulated by central dopamine receptor status. We studied apomorphine-induced increase in blood glucose levels in Parkinson's disease compared with those in Parkinsonian syndromes unresponsive to dopaminergic drugs. Results indicate that apomorphine-induced blood glucose level increases are significant only in Parkinson's disease. As in the animal, this could possibly be explained by central dopamine receptor status.

PubMed: 8149364

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001688

Links to Exploration step

pubmed:8149364

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine increases blood glucose concentrations in Parkinson's disease.</title>
<author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Hôpital Pellegrin, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Neurologie, Hôpital Pellegrin, Bordeaux</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fouillet, N" sort="Fouillet, N" uniqKey="Fouillet N" first="N" last="Fouillet">N. Fouillet</name>
</author>
<author><name sortKey="Henry, P" sort="Henry, P" uniqKey="Henry P" first="P" last="Henry">P. Henry</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1994">1994</date>
<idno type="RBID">pubmed:8149364</idno>
<idno type="pmid">8149364</idno>
<idno type="wicri:Area/PubMed/Corpus">001688</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001688</idno>
<idno type="wicri:Area/PubMed/Curation">001647</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001647</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Apomorphine increases blood glucose concentrations in Parkinson's disease.</title>
<author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Hôpital Pellegrin, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Neurologie, Hôpital Pellegrin, Bordeaux</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fouillet, N" sort="Fouillet, N" uniqKey="Fouillet N" first="N" last="Fouillet">N. Fouillet</name>
</author>
<author><name sortKey="Henry, P" sort="Henry, P" uniqKey="Henry P" first="P" last="Henry">P. Henry</name>
</author>
</analytic>
<series><title level="j">Clinical neuropharmacology</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1994" type="published">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Apomorphine (adverse effects)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Blood Glucose (metabolism)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease, Secondary (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Data from studies indicate that blood glucose levels may be influenced by stimulation of central D1 and D2 dopamine receptors. This is modulated by central dopamine receptor status. We studied apomorphine-induced increase in blood glucose levels in Parkinson's disease compared with those in Parkinsonian syndromes unresponsive to dopaminergic drugs. Results indicate that apomorphine-induced blood glucose level increases are significant only in Parkinson's disease. As in the animal, this could possibly be explained by central dopamine receptor status.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8149364</PMID>
<DateCreated><Year>1994</Year>
<Month>05</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>1994</Year>
<Month>05</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN>
<JournalIssue CitedMedium="Print"><Volume>17</Volume>
<Issue>1</Issue>
<PubDate><Year>1994</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Clinical neuropharmacology</Title>
<ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Apomorphine increases blood glucose concentrations in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>92-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Data from studies indicate that blood glucose levels may be influenced by stimulation of central D1 and D2 dopamine receptors. This is modulated by central dopamine receptor status. We studied apomorphine-induced increase in blood glucose levels in Parkinson's disease compared with those in Parkinsonian syndromes unresponsive to dopaminergic drugs. Results indicate that apomorphine-induced blood glucose level increases are significant only in Parkinson's disease. As in the animal, this could possibly be explained by central dopamine receptor status.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tison</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Service de Neurologie, Hôpital Pellegrin, Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fouillet</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Henry</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Neuropharmacol</MedlineTA>
<NlmUniqueID>7607910</NlmUniqueID>
<ISSNLinking>0362-5664</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber>
<NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year>
<Month>2</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1994</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1994</Year>
<Month>2</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8149364</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001647 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001647 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:8149364
   |texte=   Apomorphine increases blood glucose concentrations in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:8149364" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Apomorphine increases blood glucose concentrations in Parkinson's disease.

Apomorphine increases blood glucose concentrations in Parkinson's disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki